Plasma Exchange as an Effective Salvage Treatment for Atypical IEC-HS Complicating CAR-T Therapy in Multiple Myeloma: A Case Report and Literature Review
Year: 2026
Type: preprint
Study design: Case Report
Abstract: Relapsed/refractory multiple myeloma (RRMM) poses substantial therapeutic challenges, and chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment modality. However, CAR-T therapy is often complicated by life-threatening adverse events, most notably cytokine release syndrome (CRS) and secondary hemophagocytic lymphohistiocytosis(sHLH). However distinguishing atypical Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome(IEC-HS) from conventional CRS or sHLH remains clinically difficult but is critical for patient survival. Their overlapping clinical manifestations frequently complicate accurate diagnosis and clinical management. Here, we report a patient who developed an extremely elevated interleukin-6 (IL-6) level (1,227,475 pg/mL) during CAR-T therapy and concurrently met all key diagnostic criteria for sHLH, leading to a diagnosis of severe CRS complicated with sHLH, which was atypical IEC-HS. After three courses of tocilizumab treatment proved ineffective, therapeutic plasma exchange (TPE) was performed and successfully alleviated the severe adverse events associated with CAR-T therapy. These findings indicate that TPE represents a viable therapeutic option for the atypical IEC-HS following CAR-T infusion. We comprehensively explored the diagnosis of CRS combined with sHLH in RRMM patients after CAR-T therapy through the treatment process of individual cases, with a focus on analyzing the therapeutic effect of plasma exchange. This review aims to provide evidence-based guidance and decision support for clinicians to manage these complex and potentially fatal complications, ultimately improving the prognosis of patients with atypical IEC-HS in RRMM after CAR-T therapy.
Source: Research Square
Authors: Songyun Wang(Conceptualization, Data curation, Funding acquisition, Investigation, Validation, Writing – original draft), Zesong Wang(Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Writing – review & editing), Bianfeng Zhao(Data curation, Writing – original draft), Yuanyuan Jiao(Data curation, Investigation, Writing – original draft), Erqing Yang(Data curation, Investigation, Writing – original draft), Tianjiao Wu(Data curation, Investigation, Writing – original draft), Shuangshuang Chen(Data curation, Writing – original draft), Haoyang Ma(Data curation, Investigation, Writing – original draft), Jie Li(Data curation, Writing – original draft), Huirui Wang
Institution: Henan University of Science and Technology
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7235537046
